This is a correction to: William R Strohl, Structure and function of therapeutic antibodies approved by the US FDA in 2024, Antibody Therapeutics, 2025, tbaf014, https://doi.org/10.1093/abt/tbaf014
The originally published version of this manuscript has been corrected.
On page 6, the following sentence incorrectly cited reference 148, instead of reference 124:
``The first FDA-approved anti-PD-1 mAb was Merck's pembrolizumab (Keytruda®), which was approved in September 2014 for the treatment of metastatic melanoma.''
Also on page 6, the following sentence incorrectly cited reference 124, instead of reference 125:
``Nivolumab (Opdivo®), the second FDA-approved anti-PD-1 mAb, was approved by the FDA in December 2014 for the treatment of metastatic melanoma.''
In Table 2 and 3, the four-letter suffixes which were included in the columns entitled ``Antibody'', have been removed.
Typographical errors in the names ``BeiGene'' and ``GlaxoSmithKline'' have been corrected in several places.
In the following sentence on page 9, ``each of five of the'' has been corrected to read ``each of the six'':
``Tislelizumab has a clearance at steady state of 0.153 L/d, which is lower than each of five of the other FDA-approved (pembrolizumab, nivolumab, cemiplimab, dostarlimab, retifanlimab, toripalimab) anti-PD-1 mAbs (range of 0.17–0.31 L/d) and a terminal steady state half-life (TSST1/2) of 24 days (d), which is at the higher end of the range for half-life values of the other six anti-PD-1 mAbs (range of 18–25 d).''
In the following subheading ``antibody-Enhanze®'' has been corrected to read ``antibody-hyaluronidase'':
``Newly approved antibody-Enhanze® coformulations for subcutaneous administration''.
In the following sentence, ``rituximab'' has been corrected to read ``Rituxan'':
``This relatively new alternative delivery technology, developed by Halozyme and licensed to several major antibody development companies (Table 7), can reduce delivery of high dose biologics from hours to minutes, as exemplified by the difference between rituximab (MabThera, in EU) intravenous (IV) dosing, which can take up to 3–4 h, versus Rituxan Hycela® (rituximab coformulated with rHuPH20), which can be dosed in < 10 min.''
In the caption of Table 7, ``PEGPH20'' has been corrected to read ``rHuPH20''.
Reference 228 originally incorrectly duplicated reference 91. This has been corrected and the following reference has been added to the manuscript as reference 228:
Liu L, Jacobsen FW, Everds N et al. Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro, Journal of Biological Chemistry, Volume 292, Issue 5, 1876–1883, https://doi.org/10.1074/jbc.m116.748707.
On page 14, the citation of reference 91 was mistakenly omitted from the following sentence:
``The Fc is silenced using the mutations R572C, N577G, V582C, R827C, N832G, and V837C, and the protein is non-glycosylated, owing to the N-glycosylation site N577G and N832G mutations (all in 1–982 numbering, not Eu numbering).''